Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zenocutuzumab - Merus

Next Previous
Drug Profile

Zenocutuzumab - Merus

Alternative Names: BIZENGRI; HER3 x HER2 Biclonics®; MCLA-128; Zeno; Zenocutuzomab - Merus; zenocutuzumab-zbco - Merus

Latest Information Update: 11 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merus
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists; ERBB-3 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Adenocarcinoma; Non-small cell lung cancer
  • Phase II HER2 positive breast cancer; Prostate cancer
  • Phase I/II Solid tumours
  • Preclinical Cancer

Most Recent Events

  • 05 Feb 2026 Zenocutuzumab - Merus receives Orphan Drug status for Cholangiocarcinoma (Late-stage disease, Inoperable/Unresectable, Metastatic disease) in USA
  • 12 Dec 2025 Merus has been acquired by Genmab
  • 04 Nov 2025 Zenocutuzumab - Merus receives Breakthrough Therapy status for Cholangiocarcinoma (Late-stage disease, Inoperable/Unresectable, Metastatic disease) in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top